Novo Nordisk A/s Stock News

Novo Nordisk A/S (NYSE:NVO) has received an average recommendation of “Hold” from the thirteen brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective […]

Fisher Asset Management LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,175,539 shares of the companys stock after buying an additional 93,552 shares during the quarter. Novo Nordisk A/S comprises 1.0% []

Crossmark Global Holdings Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 0.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,805 shares of the companys stock after buying an additional 110 shares during the period. Crossmark Global Holdings []

Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co , Novo Nordisk and Sanofi , which control the market for insulin.

JJJ Advisors Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 7.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,632 shares of the companys stock after acquiring an additional 183 shares during the quarter. JJJ Advisors Inc.s holdings []

According to the new market research report "Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecast to 2026",

Novo Nordisk A/S (NYSE:NVO) Stock analysts at Jefferies Financial Group cut their FY2022 earnings estimates for shares of Novo Nordisk A/S in a research note issued to investors on Tuesday, December 7th. Jefferies Financial Group analyst P. Welford now expects that the company will earn $3.66 per share for the year, down from their []

Pilot Program Leverages Continuous Objective Measurement to Identify and Address Aspects of Behavior Related to Improved Health Outcomes Ksana Health, a digital behavioral health company that uses

EUGENE, Ore.--(BUSINESS WIRE)-- #BehavioralHealth--Ksana Health, a digital behavioral health company, today announced its selection by Novo Nordisks Global Prevention Accelerator.

KUALA LUMPUR, Malaysia , Dec. 9, 2021 /PRNewswire/ -- Alcon, Novo Nordisk, Inova Pharma are recognized as the top 3 best places to work in Malaysia for 2021 according to the annual prestigious "Best Places to Work" certification program. Best Places to Work is an international certification program, considered as the ''Platinum Standard'' in identifying and recognizing top workplaces around the world, providing employers the opportunity to learn more about the engagement and the satisfaction of their employees and honour those who deliver an outstanding work experience with the highest standards in regards to working conditions. Alcon Malaysia, an affiliate of the global leader in eye care, was awarded the top position followed by Novo Nordisk Malaysia, an affiliate of the global healthcare company with more than 95 years of innovation and leadership in diabetes care. Inova Pharma, a company that develops and markets a range of over the counter and prescription medicines to Asia , Australia and New Zealand , came in the third position.

Global Self Injection Device Market Insights and Forecast to 2027 The Self Injection Device Market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details.

Businessmarketinsights Latest update on North America Drug Delivery System Market Analysis, North America Drug Delivery System market growth analysis and Projection by 2027. This report is highly predictive as it holds the overall market analysis of topmost companies into

North Star Asset Management Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 65.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,603 shares of the companys stock after purchasing an additional 7,751 shares during the quarter. North Star Asset Management Inc.s []

Novo Nordisk A/S (NYSE:NVO) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 2,580,000 shares, an increase of 22.3% from the October 31st total of 2,110,000 shares. Based on an average daily trading volume, of 917,900 shares, the short-interest ratio is currently 2.8 []